Page 12 - Biontech Se News Today

Investegate announcements from BioNTech SE, Pfizer and BioNTech Receive Positive CHMP Opinion for COMIRNATY® in Children 6 Months to less than 5 Years in the European Union

Investegate announcements from BioNTech SE, Pfizer and BioNTech Announce Positive Early Data From Clinical Trial of Omicron BA.4/BA.5-Adapted Bivalent Booster in Individuals 18 Years and Older

Investegate announcements from BioNTech SE, BioNTech and Australia’s State of Victoria Form Strategic Partnership to Establish mRNA Research Center and Manufacturing Facility

NEW YORK and MAINZ, GERMANY, September 26, 2022 — Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced they have completed a submission...

Investegate announcements from BioNTech SE, Pfizer and BioNTech Submit Application to U.S. FDA for Emergency Use Authorization of Omicron BA.4/BA.5-Adapted Bivalent Vaccine Booster in Children 5 Through 11 Years of Age

Moderna Inc. has allowed its Covid-19 vaccine to be used in a World Health Organization effort to develop mRNA shots that would increase production and access for poor countries.

Investegate announcements from BioNTech SE, Pfizer and BioNTech Receive Positive CHMP Opinion for Conversion of COMIRNATY® Conditional Marketing Authorization to Full Marketing Authorization in the European Union

Investegate announcements from BioNTech SE, Pfizer and BioNTech Receive Positive CHMP Opinion for Omicron BA.4/BA.5-Adapted Bivalent COVID-19 Vaccine Booster in European Union

Investegate announcements from BioNTech SE, BioNTech Presents Encouraging Phase 1/2 Follow-up Data for CAR-T Candidate BNT211 in Hard-To-Treat Solid Tumors at ESMO

Press release content from Globe Newswire. The AP news staff was not involved in its creation.